Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of Volenrelaxin in adults with worsening chronic heart failure with preserved ejection fraction
MOH_2024-05-23_013430Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volenrelaxin in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) (4 arms), sponsored by Eli Lilly and Company. Started Apr 2024; status: completed.
02
Drugs
volenrelaxin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on MOH_2024-05-23_013430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-23_013430.